Hematological cancers are a major cause for
the growing of mortality rate in patients worldwide.
Myeloid and lymphoid malignancies are the main
subtypes of blood cancers, and the distribution of them is
different according to the geographical details. However,
a considerable global population is affected by these
cancers and it is essential to find some blood indicators
specific for the subtypes of myeloid and lymphoid
cancers. The availability of such blood markers helps to
early diagnosis, treatment monitoring and grading of a
cancer. Expression of some receptors on normal and
diseased blood cells help the purpose as an indicator.
Tyrosine protein kinase kit (C Kit) / Ligand-Stem Cell
Factor (SCF) systems are responsible for the
hematopoietic cell proliferation, cell survival and certain
intracellular activities that takes place in the normal
condition. C Kit receptor also shows a co expression with
similar tyrosine kinase receptors which has same
functions. In this review, we study the presence of C Kit
(CD 117) on blood cells in hematological cancers to
investigate the possibility of using C Kit/SCF systems for
novel drug targets for them.
Keywords : C Kit System, SCF, Hematological Cancers, Blood Indicators.